CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer

Jereczek-Fossa, B.A.; Bossi-Zanetti, Isa; Mauro, Roberta Di; Beltramo, G.; Fariselli, Laura; Bianchi, Livia; Fodor, C.; Fossati, Piero; Baroni, Guido; Orecchia, Roberto

doi:10.1007/s00066-013-0345-y

Cited by 25 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11,12 Thirty one clinical series reporting treatment outcome (in the series of 1-69 cases of lymph node recurrence) were divided in those including patients treated with SBRT only for lymph node recurrent cancer (12 articles) [32][33][34][35][36][37][38][39][40][41][42][43] and those on the patients treated for any oligometastatic cancer to any sites including lymph nodes (19 articles). [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31] The first article of this series was published in 2005. 23 Twenty eight out of 31 articles (90%) have been published in the last 6 years (2008-2013).…”

Section: Resultsmentioning

confidence: 99%

“…Nineteen out of 31 clinical series reporting outcome included patients treated with SBRT for any site including lymph node recurrence [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31] (Table 2). Nine studies (29%) were prospective, including 1 phase I trial.…”

Section: Series Reporting Sbrt For Any Oligometastatic Site Includingmentioning

confidence: 99%

“…Several SBRT courses were proposed in some series. [15][16][17]23,[28][29][30] Concomitant systemic treatment was allowed in some series, [15][16][17][18] especially if prostate cancer patients were included (androgen deprivation).…”

Section: Case Profile and Tumor Sites Sixteen Hundred Lesionsmentioning

confidence: 99%

See 2 more Smart Citations

Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?

Jereczek‐Fossa

Ronchi

Orecchia

2015

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

a b s t r a c tObjectives: To review the available data about stereotactic body-radiotherapy (SBRT) for oligometastatic lymph node cancer recurrence. Methods:The inclusion criteria for this study were as follows: Medline search for the (1) English language (2) full paper (abstracts were excluded) on (3) adult oligometastatic solid cancer recurrence limited to lymph node that underwent SBRT (4) outcome data available and (5) published up to the 30th April 2014.Results: 38 papers fulfilling the inclusion criteria have been found: 7 review articles and 31 patient series (20 and 11 retrospective and prospective studies, respectively) including between 1 and 69 patients (636 lymph nodes). Twelve articles reported only lymph node SBRT while in 19 -all types of SBRT including lymph node SBRT were presented. Two-year local control, 4-year progression free survival and overall survival was of up to 100%, 30% and 50%, respectively. The progression was mainly out-field (10-30% of patients had a recurrence in another lymph node/nodes). The toxicity was low with mainly mild acute events and single grade 3-4 late events. When compared to SBRT for any oligometastatic cancer, SBRT for lymph node recurrence carried better prognosis and showed lower toxicity.Conclusions: SBRT is a feasible approach for oligometastatic lymph node recurrence, offering excellent in-field tumor control with low toxicity profile. The potential abscopal effect has been hypothesized as a basis of these findings. Future studies are warranted to identify the patients that benefit most from this treatment. The optimal combination with systemic treatment should also be defined.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Series Reporting Sbrt For Any Oligometastatic Site Includingmentioning

confidence: 99%

See 1 more Smart Citation

Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?

Jereczek‐Fossa

Ronchi

Orecchia

2015

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

“…On the one hand, high-end equipments and advanced technology are introduced, such as positron emission computed tomography (PET-CT), stereotactic radiotherapy (SBRT), and image-guide radiotherapy (IGRT). In spite of this, the local control of lung cancer is still not optimistic [21–23]. On the other hand, predictive biomarkers of radiosensitivity are studied as a useful strategy to monitor radiotherapy and optimize treatment plan in advance.…”

Section: Discussionmentioning

confidence: 99%

Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer

Liao

et al. 2016

Tumor Biol.

View full text Add to dashboard Cite

BackgroundRadioresistance of thoracic radiotherapy is a major bottleneck in the treatment of non-small cell lung cancer (NSCLC). Until now, there have been no effective biomarkers to predict the radiosensitivity.PurposesBased on miRNA profile screened from NSCLC cell lines with different radiosensitivity, this study was conducted to explore the correlation between plasma miRNAs and radiotherapy response in NSCLC patients, and to identify biomarkers of the radiosensitivity in NSCLC.MethodsDifferentially expressed genes were acquired from time-series gene expression profiles of radioresistant H1299 and radiosensitive H460 lung cancer cells (GSE20549). Potential miRNAs were screened from these differentially expressed genes by combining bioinformatics with GO analysis, pathway analysis, and miRNA prediction. A clinical observational study was performed to explore the correlation between candidate miRNAs and radiotherapy response. Stage IIIa–IV NSCLC patients who received two to four cycles of previous chemotherapy and underwent thoracic radiotherapy alone were included. Total RNA was purified from peripheral blood before radiotherapy, and plasma miRNAs were detected by real-time PCR (qRT-PCR). Then, tumor response, progression-free survival (PFS), and overall survival (OS) were acquired. Four miRNAs significantly different between effective and ineffective groups were further analyzed to obtain cutpoints from receiver operating characteristic (ROC) curves and the predictive value of radiosensitivity.ResultsCandidate miRNAs included 14 miRNAs screened from radioresistant genes and five from radiosensitive genes. From Jan., 2013 to Dec., 2014, 54 eligible patients were enrolled with a median follow-up of 15.3 months (range 4.6 to 31.4) by the deadline of Aug. 31, 2015. Totally, there were no case of complete response (CR), 15 of partial response (PR), 35 of stable disease (SD), and 4 of progressive disease (PD). Eight patients had no progression and 19 patients were still alive. The median PFS and OS were 6.6 months (range 2.3 to 29.3) and 15.3 months (range 4.6 to 31.4), respectively. Four miRNAs (hsa-miR-98-5p, hsa-miR-302e, hsa-miR-495-3p, and hsa-miR-613) demonstrated a higher expression in effective group (CR + PR, 15 cases) than in ineffective group (SD + PD, 39 cases). Based on each cutpoint, objective response rate (ORR) was higher in miR-high group than in miR-low group. No miRNA showed correlation with median PFS or OS.ConclusionBioinformatical analysis and clinical verification reveal the correlation between plasma miRNAs and radiosensitivity in NSCLC patients. Plasma miRNAs represent novel biomarkers to predict radiotherapy response clinically.Electronic supplementary materialThe online version of this article (doi:10.1007/s13277-016-5052-8) contains supplementary material, which is available to authorized users.

show abstract

“…Surgical resection is considered as the standard option for patients with oligometastatic lung tumors, with good results in terms of local control and survival [5]. Recently, stereotactic body radiation therapy (SBRT) has been reported as an effective option for curative treatment of oligometastatic lung tumors [6–8]. …”

Section: Introductionmentioning

confidence: 99%

Particle beam radiation therapy using carbon ions and protons for oligometastatic lung tumors

et al. 2014

View full text Add to dashboard Cite

BackgroundA study was undertaken to analyze the efficacy and feasibility of particle beam radiation therapy (PBRT) using carbon ions and protons for the treatment of patients with oligometastatic lung tumors.MethodsA total of 47 patients with 59 lesions who underwent PBRT for oligometastatic lung tumors between 2003 and 2011 were included in this study. Patient median age was 66 (range, 39–84) years. The primary tumor site was the colorectum in 11 patients (23.4%), lung in 10 patients (21.3%) and a variety of other sites in 26 patients (55.3%). Thirty-one patients (66%) received chemotherapy prior to PBRT. Thirty-three lesions were treated with 320-MeV carbon ions and 26 were treated with 150- or 210-Mev protons in 1–4 portals. A median total dose of 60 (range, 52.8–70.2) GyE was delivered at the isocenter in 8 (range, 4–26) fractions.ResultsThe median follow-up time was 17 months. The local control, overall survival and progression-free survival rates at 2 years were 79%, 54 and 27% respectively. PBRT-related toxicities were observed; six patients (13%) had grade 2 toxicity (including grade 2 radiation pneumonitis in 2) and six patients (13%) had grade 3 toxicity. Univariate analysis indicated that patients treated with a biologically equivalent dose of 10 (BED10) <110 GyE10, had a significantly higher local recurrence rate. Local control rates were relatively lower in the subsets of patients with the colorectum as the primary tumor site. No local progression was observed in metastases from colorectal cancer irradiated with a BED10 ≥ 110 GyE10. There was no difference in treatment results between proton and carbon ion therapy.ConclusionsPRBT is well tolerated and effective in the treatment of oligometastatic lung tumors. To further improve local control, high-dose PBRT with a BED10 ≥ 110 GyE10 may be promising. Further investigation of PBRT for lung oligometastases is warranted.

show abstract

CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer

Abstract: CBK-SRT is a feasible therapeutic approach for oligometastastic cancer patients that provides long-term in-field tumor control with a low toxicity profile. Further investigations should focus on dose escalation and optimization of the combination with systemic therapies.

Cited by 25 publications

References 28 publications

Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?

Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective?

Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer

Particle beam radiation therapy using carbon ions and protons for oligometastatic lung tumors

Contact Info

Product

Resources

About